(SENS) Senseonics Holdings, Common - NASDAQ
Sector: Healthcare | Industry: Medical Devices | Exchange: NASDAQ (USA) | Market Cap: 382m USD | Total Return: -33.3% in 12m
Avg Turnover: 3.80M
Qual. Beats: 0
Rev. Trend: 89.2%
Qual. Beats: 1
Warnings
Share dilution 27.5% YoY
Interest Coverage Ratio -17.5 is critical
Altman Z'' -15.00 < 1.0 - financial distress zone
Tailwinds
Confidence
Senseonics Holdings, Inc. is a medical technology firm specializing in the design and commercialization of implantable continuous glucose monitoring (CGM) systems. Its primary product line, marketed under the Eversense brand, utilizes a long-term subcutaneous sensor paired with a removable smart transmitter to provide real-time glucose data to patients and healthcare providers.
Operating within the Health Care Supplies sub-industry, the company utilizes a distribution-heavy business model to reach global markets. Unlike traditional CGMs that require frequent sensor replacements every 7 to 14 days, Senseonics focuses on long-wear technology designed to remain functional for several months to a year.
The company maintains strategic partnerships to manage fulfillment and clinical integration across its international footprint. For deeper insights into the companys financial health, consider reviewing the detailed metrics available on ValueRay. Founded in 1996, Senseonics remains a specialized player in the competitive diabetes management sector.
- FDA approval and launch of Eversense 365-day CGM system
- Commercial partnership with Ascensia Diabetes Care drives global revenue growth
- Insurance coverage expansion increases patient access and total addressable market
- Competition from Dexcom and Abbott pressures market share and pricing
- Cash burn rate and capital requirements impact balance sheet stability
| Net Income: -87.2m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.74 > 0.02 and ΔFCF/TA 2.75 > 1.0 |
| NWC/Revenue: 162.0% < 20% (prev 282.9%; Δ -120.9% < -1%) |
| CFO/TA -0.73 > 3% & CFO -75.1m > Net Income -87.2m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 3.51 > 1.5 & < 3 |
| Outstanding Shares: last quarter (45.8m) vs 12m ago 27.48% < -2% |
| Gross Margin: 52.07% > 18% (prev 7.19%; Δ 44.88% > 0.5%) |
| Asset Turnover: 42.84% > 50% (prev 27.15%; Δ 15.68% > 0%) |
| Interest Coverage Ratio: -17.50 > 6 (EBIT TTM -82.5m / Interest Expense TTM 4.71m) |
| A: 0.64 (Total Current Assets 92.3m - Total Current Liabilities 26.3m) / Total Assets 102.9m |
| B: -10.20 (Retained Earnings -1.05b / Total Assets 102.9m) |
| C: -0.87 (EBIT TTM -82.5m / Avg Total Assets 95.0m) |
| D: 0.50 (Book Value of Equity 34.3m / Total Liabilities 68.5m) |
| Altman-Z'' = -34.36 = D |
| DSRI: 1.39 (Receivables 15.1m/6.32m, Revenue 40.7m/23.7m) |
| GMI: 0.14 (GM 7.19% / 52.07%) |
| AQI: 0.21 (AQ_t 0.01 / AQ_t-1 0.06) |
| SGI: 1.72 (Revenue 40.7m / 23.7m) |
| TATA: -0.12 (NI -87.2m - CFO -75.1m) / TA 102.9m) |
| Beneish M = -3.46 (Cap -4..+1) = AA |
As of June 20, 2026, the stock is trading at USD 6.74 with a total of 1,154,235 shares traded.
Over the past week, the price has changed by -8.05%,
over one month by +21.22%,
over three months by +6.31% and
over the past year by -33.27%.
Senseonics Holdings, Common has received a consensus analysts rating of 3.50. Therefore, it is recommended to hold SENS.
- StrongBuy: 1
- Buy: 1
- Hold: 1
- Sell: 1
- StrongSell: 0
| Analysts Target Price | 13.8 | 104.7% |
P/E Forward = 21.0084
P/S = 9.3799
P/B = 11.0229
Revenue TTM = 40.7m USD
EBIT TTM = -82.5m USD
EBITDA TTM = -80.8m USD
Long Term Debt = 35.9m USD (from longTermDebt, last quarter)
Short Term Debt = 944k USD (from shortTermDebt, last quarter)
Debt = 50.4m USD (from shortLongTermDebtTotal, last quarter) + Leases 7.23m
Net Debt = -14.3m USD (calculated: Debt 50.4m - CCE 64.6m)
Enterprise Value = 367.6m USD (381.9m + Debt 50.4m - CCE 64.6m)
Interest Coverage Ratio = -17.50 (Ebit TTM -82.5m / Interest Expense TTM 4.71m)
EV/FCF = -4.84x (Enterprise Value 367.6m / FCF TTM -75.9m)
FCF Yield = -20.65% (FCF TTM -75.9m / Enterprise Value 367.6m)
FCF Margin = -186.5% (FCF TTM -75.9m / Revenue TTM 40.7m)
Net Margin = -214.2% (Net Income TTM -87.2m / Revenue TTM 40.7m)
Gross Margin = 52.07% ((Revenue TTM 40.7m - Cost of Revenue TTM 19.5m) / Revenue TTM)
Gross Margin QoQ = 59.26% (prev 53.79%)
Tobins Q-Ratio = 3.57 (Enterprise Value 367.6m / Total Assets 102.9m)
Interest Expense / Debt = 9.36% (Interest Expense 4.71m / Debt 50.4m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -65.2m (EBIT -82.5m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 3.13 (Total Current Assets 92.3m / Total Current Liabilities 29.5m)
Debt / Equity = 1.47 (Debt 50.4m / totalStockholderEquity, last quarter 34.3m)
Debt / EBITDA = 0.18 (negative EBITDA) (Net Debt -14.3m / EBITDA -80.8m)
Debt / FCF = 0.19 (negative FCF - burning cash) (Net Debt -14.3m / FCF TTM -75.9m)
Total Stockholder Equity = 67.1m (last 4 quarters mean from totalStockholderEquity)
RoA = -91.74% (Net Income -87.2m / Total Assets 102.9m)
RoE = -130.0% (Net Income TTM -87.2m / Total Stockholder Equity 67.1m)
RoCE = -80.09% (EBIT -82.5m / Capital Employed (Equity 67.1m + L.T.Debt 35.9m))
RoIC = -86.36% (negative operating profit) (NOPAT -65.2m / Invested Capital 75.4m)
WACC = 9.22% (E(381.9m)/V(432.2m) * Re(9.46%) + D(50.4m)/V(432.2m) * Rd(9.36%) * (1-Tc(0.21)))
Discount Rate = 9.46% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 73.33 | Cagr: 27.52%
[DCF] Fair Price = unknown (Cash Flow -75.9m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.04 | # QB: 0
Revenue Correlation: 89.18 | Revenue CAGR: 25.31% | SUE: 4.0 | # QB: 1
EPS current Quarter (2026-06-30): EPS=-0.62 | Chg30d=+4.60% | Revisions=+40% | Analysts=6
EPS next Quarter (2026-09-30): EPS=-0.60 | Chg30d=+6.23% | Revisions=+60% | Analysts=6
EPS current Year (2026-12-31): EPS=-2.45 | Chg30d=+1.76% | Revisions=+64% | GrowthEPS=-47.6% | GrowthRev=+76.4%
EPS next Year (2027-12-31): EPS=-2.19 | Chg30d=+10.92% | Revisions=+45% | GrowthEPS=+10.5% | GrowthRev=+57.5%
[Analyst] Revisions Ratio: +64%